Pneumosil (10-valent pneumococcal conjugate vaccine) / Serum Institute of India, Ligand - LARVOL DELTA

Real-World Impact of Pneumococcal Conjugate Vaccines on Vaccine Serotypes and Potential Cross-Reacting Non-Vaccine Serotypes. (PubMed, Vaccines (Basel)) - "The inclusion of VT 19A in PCV13, but not in PCV10, may account for the significant increase in VRT 19A cases in PCV10 countries. The slight change in VRT 6C cases in PCV13 countries compared to the significant rise in PCV10 countries suggests that PCV13 provides cross-protection for serotype 6C through serotype 6A. Cross-protection could not be determined for other VRTs, as their cases increased or remained unchanged or had insufficient data for evaluation."

Journal • Real-world evidence • Infectious Disease • Pneumococcal Infections • Pneumonia

Impact of the National Vaccination Strategy on the Prevalence of Streptococcus pneumoniae and Its Serotypes Among Clinically Healthy Children Under Six Years of Age During and After the COVID-19 Pandemic. (PubMed, Vaccines (Basel)) - "19B/19C, 6C, 15B/15C, and 19A were identified as the main serotypes. Children over 3 years of age were also more likely to carry multiple pneumococci. These findings emphasize the need to reassess childhood vaccination strategies to curb the spread of antibiotic-resistant serotypes."

Journal • Infectious Disease • Novel Coronavirus Disease • Pneumococcal Infections • Pneumonia

The evolving epidemiology of paediatric acute mastoiditis in New Zealand. (PubMed, Int J Pediatr Otorhinolaryngol) - "The national incidence in NZ of all-cause paediatric AM increased in 2022, with a significant increase in the proportion of cases attributable to S.pneumoniae."

Journal • Infectious Disease • Novel Coronavirus Disease • Pediatrics • Pneumonia

Respiratory viral detection in children hospitalized with pneumonia during periods of major population disruptions in Nepal, 2014-2018. (PubMed, J Pediatric Infect Dis Soc) - "These findings highlight the importance of viral diagnostics in pediatric pneumonia and suggest that public health measures addressing environmental conditions during disasters might help reduce respiratory infections."

Journal • Infectious Disease • Pediatrics • Pneumonia • Respiratory Diseases • Respiratory Syncytial Virus Infections

Streptococcus pneumoniae carriage, antimicrobial resistance, and serotype distribution in children and adults from Paraguay in the post-vaccinal era. (PubMed, Front Public Health) - "This study was conducted among healthy children aged 2-59 months and adults living in the same household, to determine pneumococcal carriage rates, serotype distribution, and the serotypes associated with antibiotic resistance profiles, following the introduction of PCV10/PCV13...Our findings reveal worrying trends in the epidemiology of S. pneumoniae in Paraguay, including the persistence of vaccine-type serotypes among vaccinated children and an increasing resistance to antibiotics of isolated strains. Given the critical role of carriage studies in monitoring the impact of PCV in LMICs, the public health community should explore ways to improve their feasibility and cost-effectiveness and better integrate these efforts into routine vaccine preventable disease surveillance systems."

Journal • CNS Disorders • Infectious Disease • Pediatrics • Pneumococcal Infections • Pneumonia • Respiratory Diseases

Infant Malaria Vaccine Schedule Optimization (clinicaltrials.gov) - P2 | N=1200 | Recruiting | Sponsor: PATH | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Malaria

Genomic analysis of invasive and non-invasive disease-causing Streptococcus pneumoniae isolated from children between 2014 and 2023 in Suzhou, China. (PubMed, Microb Genom) - "We found that the majority (64.8%, n=271) of samples represented serotypes that are covered by the GSK 10-valent PCV (PCV10) formulation and that even more were covered by the SII PCV10 formulation (89.2%, n=373)...In summary, the PCV13 vaccine could potentially cover over 90% of invasive and non-invasive S. pneumoniae isolates in Suzhou, China. Therefore, increasing the uptake of PCVs by including PCV13 in the NIP would lead to significant benefits for child health."

Journal • Infectious Disease • Pneumococcal Infections • Pneumonia

Economic Evaluation of PHID-CV versus PCV10-SII Compared with no Vaccination in the Philippines. (PubMed, Infect Dis Ther) - "Both vaccination strategies are superior to no vaccination, producing more health benefits at lower costs. QALYs gained are higher with PHiD-CV but at higher direct costs. Results are most sensitive to assumptions about PCV10-SII vaccine price."

HEOR • Journal • CNS Disorders • Infectious Disease • Otorhinolaryngology • Pneumococcal Infections • Pneumonia • Respiratory Diseases

Nasopharyngeal carriage, serotype, antimicrobial susceptibility and genotype of pneumococci in young healthy children attending daycare centres in Klang Valley, Malaysia. (PubMed, J Glob Antimicrob Resist) - "The notable predominance of non-vaccine serotypes (NVTs), particularly 15C and 23A, alongside significant antibiotic resistance, especially to erythromycin and tetracycline, indicates a potential epidemiological shift in the post-PCV era. These results emphasize the need for continuous surveillance to monitor serotype dynamics and antimicrobial resistance patterns in the community."

Journal • Infectious Disease • Pneumococcal Infections • Pneumonia

PRIMARY BACTEREMIA AS THE PREDOMINANT MANIFESTATION OF INVASIVE PNEUMOCOCCAL DISEASE IN PATIENTS WITH LIVER DISEASE: EXPERIENCE FROM A LIVER TRANSPLANTATION REFERRAL CENTER IN SÃO PAULO. (ESPID 2025) - "In Brazil, PCV10 has been part of the routine immunization schedule since 2010...Patients with LD present non-pneumonic forms more frequently and have higher mortality rates. The prevalence of serotypes 19A and 3 in both study populations underscores the importance of broader vaccination strategies using extended-valency PCVs."

Clinical • Infectious Disease • Pneumococcal Infections

CHARACTERISTICS OF STREPTOCOCCUS PNEUMONIAE COLONISING CHILDREN IN CYPRUS (ESPID 2025) - "At least one vaccine dose was received by 93.6%, while 36.5% and 41.6% were fully vaccinated with PCV10 and PCV13, respectively...No strain was resistant to penicillin, cefotaxime, vancomycin or linezolid...High resistance rates were noted for erythromycin(48.2%) and clindamycin(27.5%)...Most carriage strains are not covered by current available vaccines in Cyprus, highlighting the need to introduce newer vaccines. Carriage studies help monitor resistance and serotype trends."

Clinical • Infectious Disease • Pneumococcal Infections

IMPACT OF CHILDHOOD VACCINATION ON INVASIVE PNEUMOCOCCAL DISEASE IN CHILDREN IN SLOVENIA (ESPID 2025) - "Conclusions/Learning Points In Slovenia, a decrease in vaccine-serotype-related IPD cases among children has been observed following the introduction of PCV10 and PCV13. Ongoing surveillance is essential to monitor and confirm the emergence of new serotypes."

Clinical • Infectious Disease • Pneumococcal Infections

VARIATIONS IN SEROTYPE COVERAGE PROVIDED BY NEW PNEUMOCOCCAL CONJUGATE VACCINES (PCV) AS COMPARED TO PPV 23 AMONG ADULTS WITH INVASIVE PNEUMOCOCCAL DISEASE (IPD) IN COLOMBIA. (ESPID 2025) - "Background Colombia introduced pneumococcal vaccine (PCV7) in 2009, PCV 10 in 2012 and PCV13 in 2022...Conclusions/Learning Points PPV23 and PCV20 contained more IPD serotypes affecting adults than other available available PCV. This data should be taken in account when discussing about future directions of IPD prevention in Colombian adults."

Clinical • Infectious Disease • Pneumococcal Infections

LONG TERM TRENDS OF NON PCV13 SEROTYPES ASSOCIATED TO INVASIVE PNEUMOCOCCAL DISEASES (IPD) AMONG CHILDREN AND ADOLESCENTS IN COLOMBIA. A BASELINE TO ASSESS THE IMPACT OF NEW PCV VACCINES. (ESPID 2025) - "Background Introduction: Colombia introduced PCV7 in 2009, PCV 10 in 2012 and PCV13 in 2022 but few national studies on its impact have been conducted so far...Non PCV13 serotypes decreased in small children despite no specific intervention was being used against them so far. These results are a fair baseline to compare PCV impact"

Clinical • Infectious Disease • Pneumococcal Infections

COST-EFFECTIVENESS ANALYSIS OF 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINATION VERSUS STANDARD OF CARE (13-VALENT PNEUMOCOCCAL CONJUGATE VACCINATION) AND 15-VALENT CONJUGATE PNEUMOCOCCAL VACCINATION IN CHILEAN CHILDREN (ESPID 2025) - "Background After almost a decade of using lower-valent pneumococcal conjugate vaccines (PCVs) with 7-valent (PCV7) and 10-valency (PCV10), the 13-valent PCV (PCV13) was introduced to Chile's pediatric vaccination program in 2017...However, under a willingness-to-pay threshold of 1 x GDP per capita (17,000 US Dollars) per quality-adjusted life year, PCV20 was cost-effective versus both comparators. Table: Results Conclusions/Learning Points PCV20 was the most cost-effective option for childhood vaccination, averting more disease cases and deaths in the Chilean population over 10 years, versus PCV13 and PCV15."

Clinical • Cost effectiveness • HEOR • Pneumococcal vaccines • Infectious Disease • Pneumococcal Infections

PERSISTENCE OF SEROTYPE 1 INVASIVE PNEUMOCOCCAL DISEASE AMONG CHILDREN IN NEPAL NINE YEARS AFTER PCV10 INTRODUCTION (ESPID 2025) - "Conclusions/Learning Points Spn1 IPD persists among older children 7-9 years after PCV10 introduction with a booster dose. Longer use of PCV10 in this high burden setting might be needed to interrupt Spn1 transmission in older children."

Clinical • Infectious Disease • Novel Coronavirus Disease • Pneumococcal Infections

EVALUATING HEALTH AND ECONOMIC OUTCOMES ASSOCIATED WITH THE 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE VERSUS LOWER-VALENCY ALTERNATIVES IN PERUVIAN PEDIATRICS: ANALYSES WITH AND WITHOUT INDIRECT EFFECTS (ESPID 2025) - "Background Peru's pediatric national immunization program has progressively incorporated the 7-valent (PCV7), 10-valent (PCV10), and 13-valent (PCV13) pneumococcal conjugate vaccines, with the aim of reducing the burden of pneumococcal disease...Compared with comparators, PCV20 was estimated to result in larger health benefits at a lower total cost in the scenario with indirect effects versus the scenario without indirect effects. Table: Results Conclusions/Learning Points The results of this cost-effectiveness analysis indicated that childhood vaccination with PCV20 would offer superior clinical outcomes, as well as cost-effectiveness, versus PCV13 and PCV15, particularly when indirect effects were incorporated, making PCV20 the optimal option in Peru."

Clinical • HEOR • Infectious Disease • Pneumococcal Infections

ANALYZING THE COST-EFFECTIVENESS OF INTRODUCING THE 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE INTO MALAYSIA'S NATIONAL PEDIATRIC IMMUNIZATION PROGRAM (ESPID 2025) - "Background Malaysia implemented a 3-dose schedule of 10-valent pneumococcal conjugate vaccine (PCV10) in its Pediatric National Immunization Program (NIP) in late 2020, transitioning to 13-valent PCV (PCV13) in March 2023...Estimated health and economic impact of PCV20 vs PCV13 or PCV15 Conclusions/Learning Points PCV20 was the dominant vaccination strategy, predicted to reduce more pneumococcal disease burden, mortality, and costs versus PCV13 and PCV15 among Malaysian population over 10 years. These findings are important for policymakers to consider in the context of the Malaysian paediatric NIP."

Clinical • Cost effectiveness • HEOR • Infectious Disease • Pneumococcal Infections

COST-EFFECTIVENESS OF 20-VALENT VERSUS 15-VALENT PNEUMOCOCCAL CONJUGATE VACCINES FOR CHILDREN IN THE NETHERLANDS, TAKING INTO ACCOUNT INDIRECT EFFECTS AND ADULT VACCINATION (ESPID 2025) - "Epidemiological data from 2022-2024 with PCV10 in children was used, projecting population-level pneumococcal epidemiology for implementing PCV15 or PCV20...Conclusions/Learning Points Replacing PCV15 (2+1) with PCV20 (3+1) in Dutch children would result in a net health loss, as indirect effects reduce the impact of the PCV20 program for older adults. Using PCV21 in older adults could prevent this net health loss due to its inclusion of eleven non-PCV20 serotypes but would not make PCV20 cost-effective in children."

Clinical • Cost effectiveness • HEOR • Infectious Disease • Pneumococcal Infections

Health and Economic Value of Pneumococcal Conjugate Vaccine Against Antimicrobial Resistance in Brazil: An Agent-based Simulation Study (ISPOR 2025) - "We assessed the impact of PCV vaccination in Brazil over a 5-year duration under four scenarios: counterfactual of no vaccination, current 10-valent (PCV10) vaccination (assuming constant coverage), 15-valent (PCV15) vaccination (assuming same coverage rates as PCV10), and increased PCV15 coverage (increased to 95% coverage in all geopolitical zones)... By switching to PCV15 and working to improve vaccination coverage, Brazil would benefit not only from reduced diseases and healthcare costs, but also from the ability to better control the development of AMR."

Infectious Disease • Pneumococcal Infections • Pneumonia • Respiratory Diseases

Multidimensional challenges in Brazil's decision-making process of vaccines adoption: The case of childhood pneumococcal conjugate vaccines. (PubMed, J Infect Public Health) - "Our case showed the decision-making process of adopting new vaccines is country-specific and involve many levels of political prioritization and complex technical aspects, and depends on the presence of strong public health institutions."

Journal • Infectious Disease • Pneumococcal Infections

A Narrative Review of Pneumococcal Conjugate Vaccine Choices for Greater Access and Protection against Pneumococcal Diseases in the Philippines. (PubMed, Acta Med Philipp) - "Enhancing laboratory and surveillance capacity are essential to provide evidence-based decision-making in terms of existing serotype distribution and antimicrobial resistance (AMR) profile in the country. With the introduction of a new affordable formulation of a 10-valent PCV offering a comparable serotype coverage, the reassessment of choice of PCV with the consideration of all three formulations, namely PCV13, PHiD-CV, and SIIPL-PCV, may be warranted."

Journal • Infectious Disease • Pneumococcal Infections • Pneumonia

Impact of Universal PCV10 Vaccination on Invasive Pneumococcal Disease in Croatian Children. (PubMed, Pediatr Infect Dis J) - "The introduction of PCV10 significantly changed the IPD epidemiology in Croatian children. The prevalence of PCV10 isolates decreased, with the current serodistribution suggesting the need for novel pneumococcal conjugates. Given the relatively low prevalence of isolates with PCV10 and PCV13 serotypes, PCV15 and PCV20 may be the most suitable candidates for future use."

Journal • Infectious Disease • Pneumococcal Infections • Pneumonia • Respiratory Diseases

Indirect Comparison of PCV20 Immunogenicity with PCV10 in Pediatric 3 + 1 and 2 + 1 Schedules. (PubMed, Infect Dis Ther) - "The comparable immunogenicity of PCV20 versus PCV10 in 2 + 1 and 3 + 1 schedules suggests that PCV20 will have similar effectiveness for the ten serotypes included in both vaccines, including for direct protection during infancy and toddler age, while also expanding serotype coverage. Effectiveness for PCV20 needs to be confirmed in post-marketing studies."

Journal • Infectious Disease • Pediatrics • Pneumococcal Infections • Pneumonia

Back to the future? Drastic drop in serotype 19A carriage in daycare centers within two years after a second switch to PCV13 in Belgium. (PubMed, Hum Vaccin Immunother) - "After switching from PCV13 to PCV10 in 2015-2016, Belgium switched back to PCV13 in 2019...Resistance of pneumococcal strains to penicillin increased significantly over the three study years. Two years after the second switch to PCV13 in 2019, pneumococcal serotype 19A carriage decreased again significantly in Belgian children attending daycare centers."

Journal • Infectious Disease • Influenza • Pneumococcal Infections • Pneumonia • Respiratory Diseases